Recent trends in (under)treatment of hypercholesterolaemia in the Netherlands

被引:7
作者
Mantel-Teeuwisse, AK
Verschuren, WMM
Klungel, OH
de Boer, A
Kromhout, D
机构
[1] Univ Utrecht, UIPS, Dept Pharmacoepidemiol & Pharmacotherapy, NL-3508 TB Utrecht, Netherlands
[2] Natl Inst Publ Hlth & Environm, Ctr Prevent & Hlth Serv Res, NL-3720 BA Bilthoven, Netherlands
[3] Natl Inst Publ Hlth & Environm, Nutr & Consumer Safety Div, NL-3720 BA Bilthoven, Netherlands
关键词
antilipaemic agents; cardiovascular diseases; drug therapy; hypercholesterolaemia;
D O I
10.1111/j.1365-2125.2004.02152.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim To assess recent trends in undertreatment of hypercholesterolaemia (1998-2002). Methods Data were obtained from the third cross-sectional examination of the Monitoring Project on Risk Factors for Chronic Diseases (n = 4878; age 31-70 years), conducted in the Netherlands. Treatment eligibility was established according to Dutch guidelines. Data from the second examination (1993-1997) were used to assess time trends. The association between demographic variables, cardiovascular disease risk factors, drug use and lipid-lowering medication was assessed using multivariable logistic regression. Results Overall, 45.9%[95% confidence interval (CI) 41.4, 50.4] of respondents eligible for treatment were treated, and 17.4% (95% CI 13.9, 20.9) were both treated and controlled (1998-2002). Treatment increased significantly after 1995, showed a slight decrease in subsequent years until 2000, when treatment increased again. Subgroups less frequently treated for primary prevention included among others males [odds ratio (OR) = 0.08; 95% CI 0.03, 0.21], younger patients (OR = 0.93 per year; 95% CI 0.88, 0.98), diabetics (OR = 0.19; 95% CI 0.07, 0.56), untreated hypertensives (OR = 0.21; 95% CI 0.09, 0.49) and current smokers (OR = 0.09; 95% CI 0.03, 0.25). In secondary prevention, patients with a history of stroke were less likely to receive treatment (OR = 0.41; 95% CI 0.18, 0.94) compared with patients with a history of ischaemic heart disease. Conclusions Treatment of hypercholesterolaemia has steadily increased over the past 10 years in the Netherlands. However, at present still less than one out of two eligible for treatment is treated, and only about one out of six is both treated and controlled.
引用
收藏
页码:310 / 316
页数:7
相关论文
共 25 条
[21]   Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):: a multicentre randomised controlled trial [J].
Sever, PS ;
Dahlöf, B ;
Poulter, NR ;
Wedel, H ;
Beevers, G ;
Caulfield, M ;
Collins, R ;
Kjeldsen, SE ;
Kristinsson, A ;
McInnes, GT ;
Mehlsen, J ;
Nieminen, M ;
O'Brien, E ;
Östergren, J .
LANCET, 2003, 361 (9364) :1149-1158
[22]  
*STICHT FARM KENG, 2003, DAT FEIT 2003
[23]  
Stoverinck MJM, 1996, J FAM PRACTICE, V43, P567
[24]   Drug prescription in men and women with type-2 diabetes in Stockholm in 1995 and 2001:change over time [J].
Wändell, PE ;
Gåfvels, C .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 58 (08) :547-553
[25]  
Wood D, 1998, EUR HEART J, V19, P1434